In the first suite of Phase II clinical studies for its “vascular disrupting agent (VDA)”, “CYT997” the dosing of patients has been commenced by ‘Cytopia Limited’. The activity of this anti-cancer compound in specific cancer types which are highly unmet medical need and poor diagnosis will be investigated by these studies.

In the treatment of vascular tumors VDAs are a new class of drugs to treat cancer and have the potential for best sales. A dual action mechanism of CYT997 shuts down the established blood vessels that supply nutrients and oxygen to the tumor and also direct cyto-toxic properties. The compound was discovered by Cytopia scientists in 2003 can be administered orally as well as intravenously. To commence Phase I study an Investigational New Drug application was accepted by the US Food and Drug Administration in 2005.

Cytopia commences dosing in its first Phase II study, finalized preparations for its second Phase II study, concluded its first Phase I safety and tolerability study with intravenous administration and continued dose-escalation in its Phase I capsule dosing study during the 2008 financial year.

Clinical Programs

After the conclusion of its initial Phase I study ‘Cytopia’ commenced dosing in it first Phase II trial in patients with refractory or relapsed multiple myeloma in January 2008. An extensive body of preclinical studies including studies in cells from heavily pre-treated patients was followed by this clinical study. In this clinical study ‘CYT997’ established the significant anti-myeloma activity. The utility of the drug further is the main point of the Phase II studies in conventional solid tumors is extended by the potential activity of this compound in the multiple myeloma. Cytopia also aims to file an Orphan Drug Designation application in the US which gives development benefits including extended patent protection and increased regulatory consultation for this drug in multiple myeloma within 3 months.

continue reading A Report on the Clinical Trial of CYT997, the Anti-Cancer Drug

Almost 25 million Americans are affected with ‘Osteoporosis’ every year and 80% of these people are women, according to a recent report of the ‘National Osteoporosis Foundation’. This disease is mainly responsible for thinning of the bones and this may result in to hip fractures and spinal fractures in addition to some extreme complications leading to severe health problems, the report says.

The “Bisphosphonates (BF)” is the compounds that are generally prescribed for patients suffering with this kind of disorders.”Fosamax”, the ‘alendronate sodium compound’, is one such very popular class of drugs which helps in preventing bone fractures. In ‘Osteoporosis ‘patients who are also suffering from some cancerous disease, this drug prevents bone metastases and other related skeletal problems. The types of cancers may include multiple myeloma, metastatic breast cancer, and prostate cancer.

continue reading Bisphosphonates Work in Osteoporosis but Not Effective in Osteonecrosis